- Home
- MYGN vs GUG Comparison
MYGN vs GUG Comparison
Compare MYGN & GUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- GUG
- Stock Information
- Founded
- MYGN 1991
- GUG 2021
- Country
- MYGN United States
- GUG United States
- Employees
- MYGN N/A
- GUG N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GUG Trusts Except Educational Religious and Charitable
- Sector
- MYGN Health Care
- GUG Finance
- Exchange
- MYGN Nasdaq
- GUG Nasdaq
- Market Cap
- MYGN 625.5M
- GUG 524.4M
- IPO Year
- MYGN 1995
- GUG N/A
- Fundamental
- Price
- MYGN $6.65
- GUG $15.07
- Analyst Decision
- MYGN Hold
- GUG
- Analyst Count
- MYGN 14
- GUG 0
- Target Price
- MYGN $13.23
- GUG N/A
- AVG Volume (30 Days)
- MYGN 1.1M
- GUG 108.9K
- Earning Date
- MYGN 11-03-2025
- GUG 01-01-0001
- Dividend Yield
- MYGN N/A
- GUG 9.67%
- EPS Growth
- MYGN N/A
- GUG N/A
- EPS
- MYGN N/A
- GUG N/A
- Revenue
- MYGN $825,300,000.00
- GUG N/A
- Revenue This Year
- MYGN $0.06
- GUG N/A
- Revenue Next Year
- MYGN $5.68
- GUG N/A
- P/E Ratio
- MYGN N/A
- GUG N/A
- Revenue Growth
- MYGN 0.21
- GUG N/A
- 52 Week Low
- MYGN $3.76
- GUG $12.71
- 52 Week High
- MYGN $16.83
- GUG $15.06
- Technical
- Relative Strength Index (RSI)
- MYGN 41.25
- GUG 31.28
- Support Level
- MYGN $6.25
- GUG $15.27
- Resistance Level
- MYGN $6.83
- GUG $15.69
- Average True Range (ATR)
- MYGN 0.43
- GUG 0.25
- MACD
- MYGN -0.09
- GUG -0.05
- Stochastic Oscillator
- MYGN 23.90
- GUG 2.08
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About GUG Guggenheim Active Allocation Fund of Beneficial Interest
Guggenheim Active Allocation Fund is a diversified closed-end management investment company. The fund's investment objective is to maximize total return through a combination of current income and capital appreciation. The company invests in both fixed-income and other debt instruments selected from a variety of sectors and credit qualities, and may also invest in equities. It uses tactical asset allocation models to determine the optimal allocation of its assets between fixed-income and equity securities. A majority of its investments are made in corporate bonds and the rest in senior floating rate interests, asset-backed securities, preferred stocks, and other securities.